Age

50–any

Sex

MALE

Healthy volunteers

Not accepted

Korean prostate cancer over 50 years old with pathological confirmation
Patients receiving GnRH antagonist or GnRH agonist plus anti- androgen combination within 6 months since starting.
Patients measured bone density level before starting to receive hormone therapies above.

Patients who are treated other anti-osteoporosis drugs and who are treated bisphosphate due to BMD T score below -3.0.
Patients who are hard to be analysed by attach to other bone disease.
Patients who are hard to be analysed by limitation of chart record according to investigators'discretion.

Comparison of Bone Mineral Loss in Prostate Cancer Patients Who is Receiving GnRH Agonist and -Plus Anti-androgen Agent